Analysis of the Potent Prognostic Factors in Luminal-Type Breast Cancer

• Published in: Journal of breast cancer Vol. 15; no. 4; pp. 401 - 406
• Main Authors: Kim, Han-Sung, Park, Inseok, Cho, Hyun Jin, Gwak, Geumhee, Yang, Keunho, Bae, Byung Noe, Kim, Ki Whan, Han, Sehwan, Kim, Hong-Joo, Kim, Young-Duck
• Format: Journal Article
• Language: English
• Published: Korea (South) Korean Breast Cancer Society 01.12.2012; 한국유방암학회
• Subjects: Original; 일반외과학; Bcl-2; Breast neoplasms; Prognosis
• ISSN: 1738-6756; 2092-9900
• DOI: 10.4048/jbc.2012.15.4.401

Luminal-type breast cancer has a good prognosis compared to other types, such as human epidermal growth factor receptor 2 and triple negative types. Luminal-type breast cancer is classified into luminal A and B, according to the proliferation index. We investigated the clinicopathological factors that affect the prognosis of the luminal-type subgroups. We reviewed the medical records and the pathologic reports of 159 luminal-type breast cancer patients who were treated between February 2005 and November 2007. We divided luminal-type breast cancer into luminal A and B, according to Ki-67 (cutoff value, 14%) and analyzed the clinicopathologic factors, such as age at diagnosis, intensity score of estrogen receptor and progesterone receptor, histologic grade, and Bcl-2. Moreover, we compared the disease-free survival (DFS) of each group. In the univariate analysis, age (p=0.004), tumor size (p=0.010), lymph node metastasis (p=0.001), and Bcl-2 (p=0.002) were statistically significant factors in luminal-type breast cancer. In the multivariate analysis, lymph node (p=0.049) and Bcl-2 (p=0.034) were significant relevant factors in luminal-type breast cancer. In the subgroup analysis, the increased Bcl-2 (cutoff value, 33%) was related with a longer DFS in the luminal B group (p=0.004). In our study, luminal A breast cancer showed a longer DFS than luminal B breast cancer, further, Bcl-2 may be a potent prognostic factor in luminal-type breast cancer.